Precision BioSciences (DTIL) presented early clinical data and pipeline updates at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, highlighting progress across two gene-editing programs built around its proprietary ARCUS nuclease platform.
The company reported cash and cash equivalents of $112 million at the end of Q2 2026, with a current ratio of 12.82. Management said the balance sheet provides a runway through 2028, excluding partnered program milestones.
Precision's ARCUS platform centers on three differentiators the company says set it apart from CRISPR-based approaches: a single-component design that simplifies delivery, a smaller protein size than Cas9, and the ability to enable homology-directed repair for precise gene insertion.
The most significant data update came from PBGENE-HBV, the company's experimental therapy for chronic hepatitis B targeting cccDNA, the viral reservoir driving persistent infection. In the Phase I ELIMINATE-B trial, 16 patients have received 38 total administrations to date. After two doses, patients showed a one-log reduction in cccDNA-derived transcripts, with cumulative editing observed after a third dose. All 10 patients with detectable pre-genomic RNA at baseline achieved durable undetectable pgRNA levels, and the effect appeared independent of baseline S antigen levels. Safety was initially a concern—repeat lipid nanoparticle dosing triggered hypotension and transaminase elevations—but after precision adjusted the infusion protocol in 2026 by extending duration, increasing steroid dosing and adding prophylactic saline, no further hypotensive events or LNP-related transaminase effects occurred. The company is expanding dosing cohorts at 0.4 mg/kg and 0.65 mg/kg to select a Phase II dose, with a data update expected before year-end, likely at the AASLD conference in November.
In Duchenne muscular dystrophy, PBGENE-DMD targets exons 45 through 55—covering roughly 60% of DMD patients with mutations in that hotspot—to restore near full-length dystrophin via a single treatment. Dosing began in August 2026 at Arkansas Children's Hospital, with Washington University in St. Louis as the second active site. The protocol requires an eight-week interval between the first three patients, with muscle biopsies scheduled before treatment and at three and twelve months. Preclinical studies showed 20% to 25% dystrophin expression, a level management noted could be clinically meaningful given natural history data suggesting as little as 5% near full-length dystrophin may confer benefit. The AAV dose of 1 × 10^14 vg/kg is roughly 30% lower than VYSEVIDYS's dose and below REGENXBIO's up to 2 × 10^14 vg/kg. Manufacturing achieves a 90% full capsid ratio versus roughly 50% in earlier programs. The program carries Orphan Drug, Fast Track and Rare Pediatric Disease Priority Review Voucher designations. Initial DMD safety data is expected by year-end 2026, with biopsy results and functional assessments following through 2027.
The company also has partnered programs with iECURE advancing an ornithine transcarbamylase deficiency gene insertion program using ARCUS and with azers-cel progressing a CAR-T program rooted in Precision-originated assets.
DTIL shares traded around $6.63 on September 16, down 8.4% for the week but up 59% year-to-date and 46% over the past year. Analyst price targets range from $18 to $60.
